Baimai Bio completed the Series A financing of over 50 million yuan

Biomai is a tumor immunotherapy drug developer. Its core direction is to develop innovative drug preparations for tumor immunotherapy. It is expected to synergize with existing clinical tumor treatment technologies and significantly enhance its efficacy. At the same time, the company is still Research and development of new interventional therapy technology for tumors and new cross-biological barrier macromolecular carrier technology. Recently, Baimai Bio completed the A round of financing of over 50 million yuan. This round of financing was exclusively invested by Linghang New Territories. The proceeds from this financing will be used to promote the research and development and clinical trials of the company’s tumor immunotherapy platform pipeline, as well as the construction of other platform technologies, while further improving the research and development team and expanding the research and development site.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.